CDER Director George Tidmarsh said on two separate events last week that he thought advisory committee meetings for specific ...

AstraZeneca in January also stopped its $610 million plans to construct a vaccine R&D and manufacturing site in the U.K.

While Eli Lilly’s orforglipron is top of mind heading into the European Association for the Study of Diabetes meeting this ...

After decades without much movement, a handful of new treatments for this rare autoimmune disease are now approved, and ...

A depleter of pathogenic T cells, rosnilimab’s novel MOA generated a differentiated efficacy, tolerability and safety profile in recent Phase 2b study ...

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House ...

A draft executive order obtained by The New York Times purports to clamp down on the pharmaceutical industry's ability to buy ...

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This webinar will ...

While a win for consumers, the regulatory action did nothing to stem the manufacture of compounded versions of the popular ...

LB Pharma has finally done it. The biotech IPO stalemate has been broken, with the neuroscience-focused company landing on ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...